Suven Life Sciences share news, announcements and annual reports
NSE: SUVENBSE: 530239Healthcare ServicesSmall Cap
Suven Life Sciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Oct 2003 on NSE
Last close ₹258.85down ₹5.35 (2.03%)BSE ₹258.10
Share price at the NSE close on 30 Oct 2026. Previous close ₹264.20.
30 Oct: open ₹263.50, high ₹265.65, low ₹257.00
52-week range of traded prices to 30 Oct 2026
₹124.11Low, 24 Mar 2026₹403.35High, 1 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹7,314 Cr806th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −100.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −63.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,27,67850.0% delivered
Suven Life Sciences orders, deals and press releases
305 filed, newest first. Page 7 of 7.
Jul 2007
5 Jul · Business
Press release dated July 05, 2007, titled "Suven Life Sciences presenting Pre-clinical data of their NCE's SUVN-502 and SUVN-507 at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience to be held at Melbourne, Australia". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2007
11 Jun · Business
Press release dated June 11, 2007, titled "Suven's Unit-III receives US FDA Acceptance". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2007
26 Apr · Business
Press release dated April 26, 2007, titled "Suven's yearly revenues Increase by 38%; PAT up by 33%; R&D spend at 24% of Revenue". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2007
9 Jan · Business
Press release dated January 09,2007, titled "Suven Life Sciences secures a patent from European Patent Office (EPO) on Novel Serotonin Receptor Ligands and the treatment of Disorders associated with Neurodegenarative diseases". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Jan · Business
News release dated January 08,2007, titled "Suven secures OHSAS 18001 & ISO 14001 certification". The details of the news release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.